Amarin (NASDAQ:AMRN) Issues Quarterly Earnings Results

Amarin (NASDAQ:AMRN) released its earnings results on Wednesday. The biopharmaceutical company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.18, reports. Amarin had a negative return on equity of 0.20% and a negative net margin of 14.56%. The business had revenue of $39.55 million for the quarter, compared to the consensus estimate of $43.76 million.

Here are the key takeaways from Amarin’s conference call:

• Positive Sentiment: Amarin reported its first profitable quarter in two years, with Q3 net income of $245,000 versus a $7.7 million loss a year earlier, $9 million in positive operating cash flow, and $324 million in cash and investments with no debt.
• Positive Sentiment: International momentum remained strong: European VAZKEPA in-market demand rose an estimated 68% year over year, total global partner demand increased 55%, and launches in Poland, Singapore, and South Korea are expanding the commercial opportunity.
• Negative Sentiment: Q3 revenue fell to $39.6 million from $49.7 million, primarily because U.S. pricing pressure and generic competition reduced net selling prices despite stable branded prescription volume; management expects pricing pressure to continue into 2027.
• Positive Sentiment: Amarin maintained a 47% share of the U.S. IPE market, reduced operating expenses by 44% year over year, improved gross margins sequentially through renegotiated supply contracts, and expects positive operating cash flow for the full year.
• Neutral Sentiment: The investigator-led EMT-2 colorectal cancer trial did not meet its primary progression-free-survival endpoint but showed a statistically significant 32% reduction in the hazard of death on overall survival; Amarin is evaluating the data and potential commercial and development paths, including possible partnerships.

Amarin Stock Up 6.6%

Shares of AMRN stock opened at $12.74 on Thursday. The company has a 50 day moving average price of $13.04 and a 200-day moving average price of $14.35. Amarin has a 52 week low of $11.25 and a 52 week high of $18.50. The firm has a market capitalization of $269.11 million, a PE ratio of -12.87 and a beta of 0.76.

Amarin News Roundup

Here are the key news stories impacting Amarin this week:

• Positive Sentiment: Amarin returned to profitability. The company reported third-quarter net income of approximately $245,000, or $0.2 million, compared with a loss in the year-ago period. Adjusted earnings of $0.01 per share exceeded analysts’ consensus estimate of a $0.10 loss, suggesting that cost reductions are improving the company’s financial performance. Amarin Reports 2026 Third Quarter Financial Results
• Positive Sentiment: International momentum was a key catalyst. Management pointed to a 68% increase in European demand and continued progress under its fully partnered international commercial strategy. This growth could help diversify Amarin’s revenue base and reduce its dependence on the U.S. market. Amarin Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Revenue fell short of expectations. Quarterly revenue was $39.55 million, below the $43.76 million analyst consensus, indicating that the return to profit was driven primarily by lower operating expenses rather than stronger overall sales. Amarin also maintained U.S. market-share leadership. Amarin Q3 Earnings Snapshot
• Negative Sentiment: U.S. pricing pressure and a roughly 20% revenue decline remain risks. Investors will likely want evidence that international growth can offset weaker domestic sales and that cost savings can be sustained. Amarin Returns to Quarterly Profit

Wall Street Analysts Forecast Growth

AMRN has been the topic of a number of analyst reports. Wall Street Zen cut shares of Amarin from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. JPMorgan Chase & Co. started coverage on shares of Amarin in a research note on Friday, August 21st. They set an “underweight” rating and a $13.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a research note on Thursday, October 15th. Finally, Zacks Research raised shares of Amarin from a “hold” rating to a “strong-buy” rating in a report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $13.00.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. Its principal product is VASCEPA (icosapent ethyl), a prescription omega-3 fatty-acid medicine derived from highly purified eicosapentaenoic acid.

VASCEPA was initially approved in the United States to help lower triglyceride levels in certain patients and later received expanded approval to reduce the risk of cardiovascular events in eligible adults with elevated cardiovascular risk.